Drug Type Small molecule drug |
Synonyms 3,3'-((3-Hydroxyphenyl)azanediyl)dipropionic Acid Derivatives |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacterial Infections | Preclinical | United States | 15 May 2025 | |
Bacterial Infections | Preclinical | United States | 15 May 2025 | |
Bacterial Infections | Preclinical | Lithuania | 15 May 2025 | |
Bacterial Infections | Preclinical | Lithuania | 15 May 2025 | |
Head and Neck Neoplasms | Preclinical | United States | 15 May 2025 | |
Head and Neck Neoplasms | Preclinical | United States | 15 May 2025 | |
Head and Neck Neoplasms | Preclinical | Lithuania | 15 May 2025 | |
Head and Neck Neoplasms | Preclinical | Lithuania | 15 May 2025 |